<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordOutput xmlns:ns2="local" id="358172"><TitleDisplay>The Effect of Plasma Proteins on Periodontal Tissue Regeneration</TitleDisplay><TitleOfficial>The Effect of Plasma Rich in Growth Factors (PRGF) on Periodontal Tissue Regeneration</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="ISRCTN">ISRCTN67624527</Identifier><Identifier type="Organisational Study">2903</Identifier><Identifier type="Trial Acronym">PRGF</Identifier></Identifiers><Indications><Indication id="414">Periodontal disease</Indication></Indications><BiomarkerNames><BiomarkerName id="54761" role="Therapeutic effect marker" type="Structural (imaging)">Gingiva</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Endoret (PRGF)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>surgical debridement</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>surgical debridement</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="20544" type="Company"><TargetEntity id="4296787325" type="organizationId">University of Bristol</TargetEntity></SourceEntity><SourceEntity id="414" type="ciIndication"><TargetEntity id="10034536" type="MEDDRA"></TargetEntity><TargetEntity id="D010510" type="MeSH"></TargetEntity><TargetEntity id="-1940926743" type="omicsDisease"></TargetEntity><TargetEntity id="4963" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20544">University of Bristol</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Medical device</Category><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>60</PatientCountEnrollment><DateStart>2018-05-01T00:00:00Z</DateStart><DateEnd type="estimated">2028-05-01T00:00:00Z</DateEnd><DateChangeLast>2018-11-20T22:03:25Z</DateChangeLast><DateAdded>2018-10-30T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Bristol Dental Hospital</Affiliation><Name>Prof West</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Willing to participate and voluntary written informed consent&lt;/li&gt;&lt;li&gt;Aged &gt;/= 18 years&lt;/li&gt;&lt;li&gt;Willing, able and likely to comply with all study procedures and restrictions&lt;/li&gt;&lt;li&gt;Good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history or oral examination&lt;/li&gt;&lt;li&gt;At least  two vertical interproximal periodontal defects in different quadrants of the mouth as evidenced by radiographic investigation&lt;/li&gt;&lt;li&gt;Full mouth Turesky plaque index score&amp;lt; 2&lt;/li&gt;&lt;li&gt;Non-smoker or have stopped smoking for &gt; 6 months prior to surgery&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Pregnant or who are intending to become pregnant over the duration of the study&lt;/li&gt;&lt;li&gt;Breastfeeding&lt;/li&gt;&lt;li&gt;Current or recurrent disease/dental pathology that could affect the assessments&lt;/li&gt;&lt;li&gt;Bleeding disorders&lt;/li&gt;&lt;li&gt;Immuno-compromised&lt;/li&gt;&lt;li&gt;Current or relevant previous history of serious, severe or unstable physical or psychiatric illness, or any medical disorder that may require treatment or make the participant unlikely to fully complete the study, or any condition that presents undue risk from the study products or procedures&lt;/li&gt;&lt;li&gt;Tooth with less than grade I mobility&lt;/li&gt;&lt;li&gt;Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients&lt;/li&gt;&lt;li&gt;Use of antibiotics one month prior to start of the study&lt;/li&gt;&lt;li&gt;Participation in another clinical study or receipt of an investigational drug within 10 days of the screening visit&lt;/li&gt;&lt;li&gt;Recent history of alcohol or other substance abuse&lt;/li&gt;&lt;li&gt;Member of the study site or a family relative. The study site for this protocol is the Clinical Trials Unit in the Bristol Dental Hospital. Employees of the Bristol Dental Hospital not associated with the Clinical Trials Unit are eligible to participate&lt;/li&gt;&lt;li&gt;Any participant who, in the judgement of the investigator, should not participate in the study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>To determine whether PRGF supports the predictable regeneration of the lost periodontal tissue by assessing clinical attachment levels using: bleeding on probing, pocket depth (mm), gingival recession measured from the amelo-cemental junction (mm), clinical attachment level (gingival recession plus pocket depth in mm), Width of keratinized mucosa at the surgical site (mm), biotype of the gingiva (thin/thick), Turesky plaque index (0 to 5), suppuration, mobility - 0, I, II, III, furcation - 0, I, II, III, radiograph of each surgical site</Description><Timeframe>At the baseline and 8 to 12 weeks following each surgery</Timeframe></Measure><Measure><Description>To determine whether PRGF supports the predictable regeneration of the lost periodontal tissue by assessing clinical attachment levels using: photograph of each surgical treatment site during surgery</Description><Timeframe>During surgery</Timeframe></Measure><Measure><Description>To determine whether PRGF supports the predictable regeneration of the lost periodontal tissue by assessing clinical attachment levels using: bony defect classification (1, 2, 3) (to be recorded once exposed)</Description><Timeframe>To be recorded once exposed</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Determine whether the use of PRGF in periodontal regeneration surgery is more effective than a conventional surgical approach alone in improving clinical attachment loss by assessing clinical attachment levels, through the same method as per the primary outcome measure</Description><Timeframe>At the baseline and 8 to 12 weeks following each surgery</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this trial is to investigate the effect of surgical placement of PRGF (marketed as PRGF/Endoret) on enhancing tissue regeneration in patients with vertical interproximal periodontal defects compared to surgical treatment without the placement of PRGF.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients  who fulfil the entrance criteria of at least 2 vertical interproximal defects present in different quadrants in the mouth will be randomized using a split-mouth design to receive either treatment A or B to each of the sites according to a predetermined randomization schedule. &lt;/para&gt;&lt;para&gt;For treatment procedure A, surgery on vertical interproximal defect one will include the use of PRGF, with the second surgery on defect two consisting of surgical debridement alone, without the use of PRGF. &lt;br/&gt;For treatment procedure B, surgery on vertical interproximal defect one will consist of surgical debridement alone, without the use of PRGF, with the second surgery on defect two  including the use of PRGF. &lt;/para&gt;&lt;para&gt;Following each surgical procedure, the patient will be required to return to the clinic after approximately 1 to 2 weeks for routine suture removal. The patient will also be required to complete a questionnaire with regards to their oral health following each surgery using a Visual Analogue Scale (VAS). Approximately 8 to 12 weeks following each surgery, the patient  will be asked to return to the clinic for final assessment of the oral hard and soft tissues, and assessment of the surgical treatment sites with regards to tissue regeneration. The patient  will also be asked to complete a final questionnaire with regards to their oral health following each surgery. The study duration for each patient  will be approximately 10 months.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="UK"><Sites><Site><Name>Bristol Dental Hospital</Name><Address1>Bristol</Address1><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other mouth disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18265">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="16567">Subjects with Periodontal Disease</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1002">International Standard Randomised Controlled Trial Number Register (ISRCTN)</Name><Identifiers><Identifier type="ISRCTN">ISRCTN67624527</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other mouth disease" id="43598"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other mouth disease" id="43600"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other mouth disease" id="43699"><Endpoint>Clinical Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Other mouth disease" id="43700">Assessment of probing pocket depth</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other mouth disease" id="43598"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other mouth disease" id="43699"><Endpoint>Clinical Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Other mouth disease" id="43600"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other mouth disease" id="33061"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other mouth disease" id="35078"><Criterion>Subjects with specific disease</Criterion></Inclusion><Inclusion disease="Other mouth disease" id="35331"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Other mouth disease" id="35327">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other mouth disease" id="24056"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other mouth disease" id="24305"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other mouth disease" id="25616"><Criterion>Subjects with Protocol Specified Participation Status</Criterion></Exclusion><Exclusion disease="Other mouth disease" id="26112"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion><SubCriteria><SubCriterion disease="Other mouth disease" id="24630">Subjects with history of/scheduled to receive antibiotics for other indication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other mouth disease" id="27917"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion></Exclusion><Exclusion disease="Other mouth disease" id="28330"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Exclusion><Exclusion disease="Other mouth disease" id="29144"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="estimated">2028-10-10T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>125.32 Months</EnrollmentPeriod><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-10-30T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordOutput>